Fijacion de precios de mavyret?

Mavyret Pricing in Europe

The price of Mavyret (glecaprevir/pibrentasvir) in Europe is subject to negotiations between AbbVie, the manufacturer, and individual national health systems. This pricing strategy aims to balance the drug's value with its accessibility for patients. Unlike some markets, European countries often implement stringent price controls and tend to negotiate significant discounts from the list price.

Factors Influencing Mavyret's Price

Several elements contribute to the complex pricing of Mavyret:

* Value-Based Agreements: Many European countries engage in value-based agreements. These contracts link the price paid for Mavyret to its effectiveness and patient outcomes [1]. If the drug performs as expected in real-world settings, the agreed-upon price is maintained. However, if treatment fails for a significant number of patients, the price may be reduced or rebates issued [1].
* Competition: The presence of other direct-acting antivirals (DAAs) for hepatitis C influences Mavyret's price. While Mavyret offers a pan-genotypic option, the availability of alternative treatments can create pricing pressure [2].
* National Health Budgets: Each country's healthcare budget and reimbursement policies play a crucial role. Countries with higher healthcare spending capacity may be able to afford higher prices, though they still seek to optimize value [3].
* Negotiation Power: The negotiation power of national health authorities versus the pharmaceutical company is a significant factor. Centralized purchasing or strong national agencies can often secure more favorable terms for Mavyret.

Mavyret's Market Position and Exclusivity

Mavyret gained approval as a pan-genotypic treatment for all genotypes of chronic hepatitis C virus (HCV) infection in adults, including those with compensated cirrhosis or kidney disease [4]. This broad indication positions it as a versatile treatment option.

Information regarding Mavyret's specific patent expiration dates and market exclusivity periods in various European countries is available through resources like DrugPatentWatch.com [5]. These details are crucial for understanding when generic or biosimilar competition might emerge, potentially influencing future pricing dynamics.

Sources:

[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/